Show
Sort by
-
Single ascending doses of REGN7999, a monoclonal antibody inhibitor of TMPRSS6, increase serum hepcidin and cause deep, sustained reductions in serum iron in healthy human volunteers
-
ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells
-
CD8 presence and dynamics in glofitamab-treated patients with relapsed/refractory B-cell Non-Hodgkin lymphoma using the CD8-specific PET tracer Zr-89-crefmirlimab berdoxam
-
Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy : CARTITUDE-2 cohort B 18-month follow-up
-
RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM) : updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study
-
Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the ELARA trial
-
Intravenous and subcutaneous administration of RG6234, a novel GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients with relapsed/refractory multiple myeloma (RRMM) : biomarker results from a phase I study
-
CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-Cell engaging bispecific antibody glofitamab in relapsed or refractory B-cell Non-Hodgkin lymphoma
-
Five-year results and overall survival update from the phase 3 randomized study AUGMENT : lenalidomide plus rituximab (R-2) vs rituximab plus placebo in patients with relapsed/refractory indolent Non-Hodgkin lymphoma
-
Subcutaneous epcoritamab in combination with rituximab plus lenalidomide (R-2) for first-line treatment of follicular lymphoma : initial results from phase 1/2 trial